

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1752R1	Serial No. 09/613,038
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Grillo-Lopez et al.	
		Filing Date 10 Jul 2000	Group 1636

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
QW	1	4,975,278	04.12.90	Senter, P. et al.			
	2	5,417,972	23.05.95	Bhat, N. M. et al.			
	3	5,540,926	30.07.96	Aruffo, A. et al.			
	4	5,587,459	24.12.96	Uckun			
	5	5,593,676	14.01.97	Bhat, N. M. et al.			
	6	5,595,721	21.01.97	Kaminski et al.			
	7	5,677,180	14.10.97	Robinson et al.			
	8	5,686,072	11.11.97	Uhr et al.			
	9	5,693,780	02.12.97	Newman, R. A. et al.			
	10	5,721,108	24.02.98	Robinson et al.			
	11	5,736,137	07.04.98	Anderson et al.			
	12	5,786,456	28.07.98	Ledbetter, J. A. et al.			
	13	5,795,569	18.08.98	Bartley et al.			
	14	5,872,223	16.02.99	Uckun			
	15	5,877,299	02.03.99	Thomas et al.			

Duplicate
(see #5)RECEIVED
JUN 14 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	16	405,972 A1	02.01.91	EPO			
	17	540,859 B1	14.01.98	EPO			
	18	585,943 B1	11.02.98	EPO			
	19	701,130 A2	13.03.96	EPO			
	20	WO 00/06694	10.02.00	PCT			
	21	WO 00/09160	24.02.00	PCT			
	22	WO 00/27428	18.05.00	PCT			
	23	WO 00/27433	18.05.00	PCT			
	24	WO 91/13974	19.09.91	PCT			
	25	WO 93/25673	23.12.93	PCT			
	26	WO 95/03770	09.02.95	PCT			
	27	WO 95/14230	26.05.95	PCT			
	28	WO 97/13529	17.04.97	PCT			
	29	WO 97/31025	28.08.97	PCT			
	30	WO 97/34633	25.09.97	PCT			
	31	WO 98/04281	05.02.98	PCT			
	32	WO 98/16254	23.04.98	PCT			
	33	WO 99/30738	24.06.99	PCT			

Examiner

Date Considered

Quay Nguyen

12/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1752R1	Serial No. 09/613,038
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Grillo-Lopez et al.	
				Filing Date 10 Jul 2000	Group 1636
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	34	"Amgen Discontinues Development of MGDF" (press release) (September 11, 1998)			
	35	Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation" <u>Blood</u> 63(6):1424-1433 (1984)			
Duplicate QN	36	Ballester et al., "Rituximab can be safely included as part of high-dose therapy/autologous stem cell transplantation for patients with Non-Hodgkin's lymphoma" <u>Blood</u> (Abstract #4552) 92(10 Suppl. 1 part 1-2):360b-361b (Nov 15, 1998)			
	37	Bellon et al., "Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial" <u>Human Gene Therapy</u> 8:15-25 (1997)			
Duplicate QN	38	Buckstein et al., "The effects of in vivo purging with Rituxan on stem cell mobilization efficacy, harvest purity, cytokine profile and engraftment in patients with relapsed follicular lymphoma undergoing autologous stem cell transplant" <u>Blood</u> (Abstract #2672) 92(10 Suppl. 1 Part 1-2):647a (1998)			
	39	Bussel, J.B., "Autoimmune Thrombocytopenic Purpura" <u>Hematology - Oncology Clinics of North America</u> 4(1):179-191 (Feb 1990)			
	40	Christ et al., "Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response" <u>Immunology Letters</u> 57:19-25 (1997)			
Duplicate QN	41	Cook et al., "Effective Treatment of Lymphoproliferative Disease following Lung Transplantation using Monoclonal Anti-CD20 B-Cell Antibody" <u>The Journal of Heart and Lung Transplantation</u> (abstract only) 18:84-85 (January 1999)			
	42	Demidem et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs" <u>Cancer Biotherapy & Radiopharmaceuticals</u> 12(3):177-186 (1997)			
	43	Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains" <u>EMBO Journal</u> 7(3):711-717 (1988)			
Duplicate QN	44	Faye et al., "Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders" <u>Lancet</u> 352:1285 (Oct 17, 1998)			
	45	Flinn et al., "In vivo purging and adjuvant immunotherapy with Rituximab during PBSC transplant for NHL" <u>Blood</u> (Abstract #2673) 92(10 Suppl 2 part 1-2):648a (Nov 15, 1998)			
	46	George et al., "Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology" <u>Blood</u> 88(1):3-40 (Jul 1, 1996)			
Duplicate QN	47	John et al., "Anti-CD20 monoclonal antibody for the treatment of post-transplant lymphoproliferative disease in a pediatric heart transplant recipient." <u>Journal of Investigative Medicine</u> 4(2):125A (Feb 1999)			
	48	Johnston, "Rituximab-Associated Immune Thrombocytopenic Purpura" <u>Blood</u> 94(10):4386 (1999)			
	49	Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytotoxicity" <u>Leukemia Research</u> 11(12):1119-1125 (1987)			
	50	Knoell, "Clinical Aspects of Gene Therapy" <u>The Annals of Pharmacotherapy</u> 32:977-979 (September 1998)			
	51	Korholz et al., "Humoral immunodeficiency in patients after bone marrow transplantation" <u>Bone Marrow Transplantation</u> 18:1123-1130 (1996)			
Duplicate QN	52	Lee et al., "Rituxan in the treatment of cold agglutinin disease" <u>Blood</u> 92(9):3490-3491 (Nov 1, 1998)			
Examiner <i>Quang Nguyen</i>				Date Considered <i>12/23/02</i>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1752R1Serial No.
09/613,038

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Grillo-Lopez et al.Filing Date
10 Jul 2000Group
1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- Duplicate QN* 53 Levine et al., "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab" Neurology 52:1701-1704 (May 12, 1999)
- Duplicate QN* 54 Maloney et al., "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (nhl) cell lines" Blood (Abstract #2535) 88(10):637a (1996)
- 55 Mow et al., "Rituximab for the Treatment of Refractory Immune Thrombocytopenic Purpura - Case Report" Blood 94:3526 (1999)
- 56 Nadler et al., "B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes" J. Immunol. 131(1):244-250 (Jul 1983)
- 57 Nadler et al., "Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies" Progress in Hematology, Brown, E., Grune & Stratton, Inc. Vol. XII:187-225 (1981)
- 58 Nadler, L. Lymphocyte Typing II, Renling et al., Springer Verlag Vol. 2:3-37 and Appendix (1986)
- 59 Notoya et al., "Chronic cold agglutinin disease accompanied with an increase of CD20⁺/CD5⁺ cells; a case report" The Japanese Journal of Clinical Hematology (English language abstract of attached Japanese article) 35(9):881-885 (Sep 1994)
- 60 Ooto et al., "Quantitative Flowcytometric Analysis of B Cell Surface Antigens in Patients with Autoimmune Diseases" The Japanese Journal of Clinical Pathology (English language abstract of attached Japanese article) 43(4):381-384 (Apr 1995)
- 61 Pal-Scherf et al., "A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab" (Clinical Research Proposal)
- 62 Paulus et al., "Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo" Arthritis Rheum. 33(4):477-484 (Apr 1990)
- 63 Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to Rituximab" Blood (Abstract #3360) 92 (Nov 1998)
- 64 Pescovitz, "Pilot Study of Rituxin (anti-CD20) for the reduction of high titered anti-HLA antibodies in patients with renal failure awaiting renal transplant." (Clinical Trial Proposal)
- 65 Pescovitz, "Pilot study of Rituxin (anti-CD20) for the reduction of high titered anti-HLA antibodies in patients with renal failure awaiting renal transplant." (Letter to Dr. Grillo-Lopez and Protocol Concept Sheet)
- 66 Piascik, P., "New therapeutic monoclonal antibodies target kidney transplant rejection and cancer" Journal of the American Pharmaceutical Association 38(3):379-380 (May/Jun 1998)
- Duplicate QN* 67 Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" Blood 83(2):435-445 (Jan 15, 1994)
- 68 Shan et al., "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies" Blood 91(5):1644-1652 (Mar 1, 1998)
- 69 Sollinger (Letter to Dr. Bonni S. Dutcher) (December 23, 1998)
- 70 Sollinger, "Phase 2 trial using Rituxin to desensitize patients awaiting renal transplant" (Investigator Initiated Protocol Concept Worksheet)
- 71 Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation" The Journal of Immunology 135(2):973-979 (1985)
- 72 Tedder et al., "The CD20 surface molecule of B lymphocytes functions as a calcium channel" J. Cell. Biochem. (Abstract # M 023) 14D:195 (1990)

Examiner


Quay Nguyen

Date Considered

12/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1752R1Serial No.
09/613,038

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Grillo-Lopez et al.Filing Date
10 Jul 2000Group
1632
 RECEIVED
 FEB 07 2002
 TECH CENTER 1500/2800

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
QN	99 5,677,165	14.10.97	de Boer et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	No
QN	100 332,865	20.09.89	EPO				
QN	101 WO 01/03734	18.01.01	PCT				

Examiner

Date Considered

12/23/02

*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.